Aiatella develops a multi-modal Automated Image Measurement (AIM) technology that uses MRI, CT and ultrasound images to detect and quantify vascular abnormalities and changes over time. The system automates analysis so measurements take minutes, enabling clinicians to focus more on patient care. The company is led by CEO Jack Parker and is based in Helsinki, Finland. Aiatella says it is currently undergoing medical approval processes in several countries across Europe and North America, including the UK, France and the United States. The €2M funding will be used to expand operations and advance R&D efforts. No operating metrics or prior financing details were disclosed in the article.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2025